EP300 and Ewing sarcoma: Pharmacological inhibition of P300/CBP disrupts the EWS::FLI1 transcriptional complex in Ewing sarcoma, leading to senescence and vulnerability to senolytics, providing a promising therapeutic strategy for this challenging cancer.